NCT03595202

Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)

Phase I Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 20 Years – 39 Years
• Healthy volunteers: Accepted

Summary

To investigate the safety, pharmacokinetics and pharmacodynamics of TS-143 when administered 3 times a day for 10 days to healthy Japanese adult males using placebo-controlled, double-blind, dose escalation study design.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	TS-143	Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
DRUG	Placebo	Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.

Timeline

• Start date: 2017-04-03
• Primary completion: 2017-07-07
• Completion: 2017-07-07
• First posted: 2018-07-23
• Last updated: 2025-02-28

Locations

1 site across 1 country: Japan